Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Gary Fanjiang"'
Autor:
Mark C. Genovese, Juan Sanchez-Burson, MyungShin Oh, Eva Balazs, Jeffrey Neal, Andrea Everding, Tomas Hala, Rafal Wojciechowski, Gary Fanjiang, Stanley Cohen
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-11 (2020)
Abstract Background ABP 710 is being developed as a biosimilar to infliximab reference product (RP). Analytical similarity and pharmacokinetic equivalence between the two have been previously demonstrated. Here we report results from a comparative cl
Externí odkaz:
https://doaj.org/article/e2a683879e044250a24f928f8a9a03d4
Autor:
Andrea Everding, Jeffrey Neal, Éva Balázs, Stanley Cohen, Gary Fanjiang, MyungShin Oh, Juan Sánchez-Bursón, Rafal Wojciechowski, Tomas Hala, Mark C. Genovese
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-11 (2020)
Arthritis Research & Therapy
Arthritis Research & Therapy
Background ABP 710 is being developed as a biosimilar to infliximab reference product (RP). Analytical similarity and pharmacokinetic equivalence between the two have been previously demonstrated. Here we report results from a comparative clinical st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7fbf5d61aeb8f3faf3de72bad10b3d8
http://link.springer.com/article/10.1186/s13075-020-2142-1
http://link.springer.com/article/10.1186/s13075-020-2142-1
Autor:
Jennifer Liu, Vincent Chow, Richard Markus, Helen J. McBride, Gary Fanjiang, Dan Mytych, Monica Ramchandani
Publikováno v:
Advances in Therapy
ABP 501 [United States: AMJEVITA™ (adalimumab-atto); European Union: AMGEVITA® (adalimumab)] is the first approved biosimilar to adalimumab [reference product (RP)], a monoclonal antibody (mAb) targeting tumor necrosis factor-alfa (TNF-α). ABP 50
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d6eac4d0dd43c93a98708055e5d394f
http://europepmc.org/articles/PMC6822859
http://europepmc.org/articles/PMC6822859
Autor:
MyungShin Oh, Jeffrey Neal, Stanley N. Cohen, Gary Fanjiang, Juan Sánchez-Bursón, Éva Balázs, Mark C. Genovese
Publikováno v:
Abstracts Accepted for Publication.
Background ABP 710 is being developed as a biosimilar to infliximab. Both ABP 710 and infliximab reference product (RP) inhibit tumor necrosis factor-alpha and have been shown to be structurally and functionally similar in analytical assessments. In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1eb4832212d75ccb2663291beb3ace56
https://doi.org/10.1136/annrheumdis-2019-eular.4928
https://doi.org/10.1136/annrheumdis-2019-eular.4928
Autor:
Vincent Chow, Marta Starcevic Manning, Sarah A Hoofring, J Miller, Gary Fanjiang, Alexander Colbert, Melissa A. Gessner, Dan Mytych
Publikováno v:
Diagnostics and imaging procedures.
Background Adalimumab and its biosimilars are anti-tumour necrosis factor (TNF)- monoclonal antibodies that are approved in Europe as treatment for various autoimmune-related indications, including Crohn’s disease and ulcerative colitis. Despite th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a9e0d6301729e3a3ab740aadfe08eae
https://doi.org/10.1136/annrheumdis-2019-eular.6361
https://doi.org/10.1136/annrheumdis-2019-eular.6361
Publikováno v:
Clinical Pharmacology in Drug Development
This was a randomized, single‐blind, single‐dose, 3‐arm parallel‐group study. Healthy subjects were randomized to receive ABP 710 (n = 50) or infliximab reference product (RP) sourced from the United States (infliximab US; n = 50) or the Euro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b57886ef7e6937d77c22fa502463c920
https://pubmed.ncbi.nlm.nih.gov/31628783
https://pubmed.ncbi.nlm.nih.gov/31628783
Autor:
Ainsley Malone, Beth Quatrara, Kelly A. Tappenden, Thomas R. Ziegler, Gary Fanjiang, Melissa L. Parkhurst
Publikováno v:
Journal of the Academy of Nutrition and Dietetics. 113:1219-1237
The current era of health care delivery, with its focus on providing high-quality, affordable care, presents many challenges to hospital-based health professionals. The prevention and treatment of hospital malnutrition offers a tremendous opportunity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4738d273e4c7b57830eba70b8563c74d
https://doi.org/10.1016/j.jand.2013.05.015
https://doi.org/10.1016/j.jand.2013.05.015
Autor:
Dana Gelb Safran, Hong Chang, Hector P. Rodriguez, William H. Rogers, Gary Fanjiang, Ted von Glahn
Publikováno v:
Medical Care. 44:167-174
Background: There is increasing interest in measuring patients’ experiences with individual physicians, and empirical evidence supports this area of measurement. However, the high cost of data collection remains a significant barrier. Survey modes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::638836e804ee62c36d727c7aabcc723e
https://doi.org/10.1097/01.mlr.0000196961.00933.8e
https://doi.org/10.1097/01.mlr.0000196961.00933.8e
Despite growing emphasis on public reporting of health care quality data, available data are often ignored.To evaluate the usefulness of web-based physician-level data for patients choosing a new primary care physician (PCP).Patients seeking a new PC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c0d0999dc384051635d17f93036c3c3
https://europepmc.org/articles/PMC2305859/
https://europepmc.org/articles/PMC2305859/
Autor:
Gary Fanjiang, Ronald E. Kleinman
Publikováno v:
Current opinion in clinical nutrition and metabolic care. 10(3)
Malnutrition in late infancy and childhood remains a significant public health issue in developing nations as well as for those in transition to an industrialized economy. In addition, in these settings and particularly in developed nations, overweig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd143a2ad4718bb386376a66296db264
https://pubmed.ncbi.nlm.nih.gov/17414505
https://pubmed.ncbi.nlm.nih.gov/17414505